Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 eu ...
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...
The company argues that SMA costs per child range from 2.5 million ... framework” and is reimbursement expected to begin in Germany shortly. European approval is based on the completed phase ...